New York Attorney General Letitia James sued Robert Kramer, the former CEO of Emergent BioSolutions, for insider trading in connection with the production of a Covid-19 vaccine for AstraZeneca[1][3]. In 2020, Emergent was awarded contracts worth $261 million to manufacture AstraZeneca's vaccines as part of Operation Warp Speed[2][3][4]. The company ran into production problems, with large quantities of vaccine doses being contaminated and unusable[1][2][3]. Kramer became aware of the contamination, but before it was made public, on November 13, 2020, the firm approved his plan to sell shares in January and February 2021[1][3]. In doing so, he raised more than $10.1 million in stock sales, violating the Martin Act, which prohibits insider trading[1][3]. Emergent reached a settlement with prosecutors for $900,000 in penalties and will improve management's trading policies[1][3][6]. The company will report information on the business plans of senior management and the board for three years[1]. The prosecution is asking Kramer for damages, return of profits and costs[1][3].